[{"id":"1a5d5c5e-2d0c-4820-8c6b-6f33f98d1419","acronym":"INSIGHT 2","url":"https://clinicaltrials.gov/study/NCT03940703","created_at":"2021-01-18T19:24:17.010Z","updated_at":"2025-02-25T13:52:54.712Z","phase":"Phase 2","brief_title":"A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)","source_id_and_acronym":"NCT03940703 - INSIGHT 2","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET amplification","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tepmetko (tepotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 09/19/2019","start_date":" 09/19/2019","primary_txt":" Primary completion: 05/11/2023","primary_completion_date":" 05/11/2023","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-20"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"af8a3284-49b9-490f-b1b7-982ed6e7b88b","acronym":"POTENT","url":"https://clinicaltrials.gov/study/NCT05782361","created_at":"2023-03-23T14:03:00.081Z","updated_at":"2025-02-25T16:18:40.803Z","phase":"Phase 1","brief_title":"POTENT - Tepotinib in Combination with Pembrolizumab in NSCLC","source_id_and_acronym":"NCT05782361 - POTENT","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-10-01"},{"id":"0b5f1810-21e0-4d81-99c2-2da131cdd433","acronym":"VISION","url":"https://clinicaltrials.gov/study/NCT02864992","created_at":"2021-01-17T17:11:42.537Z","updated_at":"2025-02-25T16:05:05.696Z","phase":"Phase 2","brief_title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","source_id_and_acronym":"NCT02864992 - VISION","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tepmetko (tepotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/13/2016","start_date":" 09/13/2016","primary_txt":" Primary completion: 05/16/2022","primary_completion_date":" 05/16/2022","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-08-30"},{"id":"a3747950-095a-48c6-aa37-bde9bcafea6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083857","created_at":"2023-10-16T16:13:46.888Z","updated_at":"2024-07-02T16:35:06.404Z","phase":"Phase 1/2","brief_title":"PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06083857","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-05-02"},{"id":"12564864-7d8c-467b-ba26-fc5db317bd65","acronym":"","url":"https://clinicaltrials.gov/study/NCT05120960","created_at":"2021-11-16T13:54:01.498Z","updated_at":"2024-07-02T16:35:09.062Z","phase":"Phase 1","brief_title":"A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors","source_id_and_acronym":"NCT05120960","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • MET exon 14 mutation • IDH wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • MET exon 14 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tepmetko (tepotinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 04/12/2024","primary_completion_date":" 04/12/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-04-17"},{"id":"366da270-8f09-44d6-be12-90adac16a8b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06085729","created_at":"2023-10-17T15:12:33.301Z","updated_at":"2024-07-02T16:35:16.807Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","source_id_and_acronym":"NCT06085729","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1","pipe":" | ","alterations":" TP53 mutation • PTEN mutation • LDH elevation","tags":["TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PTEN mutation • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib) • cabazitaxel • Hepacid (pegargiminase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-01"},{"id":"1cf5d688-5325-4132-8563-bf21d97a76a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06106802","created_at":"2023-10-30T16:12:46.526Z","updated_at":"2024-07-02T16:35:31.209Z","phase":"Phase 2","brief_title":"Lazertinib \u0026 Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment","source_id_and_acronym":"NCT06106802","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR • BRAF • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR C797S • EGFR mutation + MET-CEP7 fusion","tags":["EGFR • BRAF • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR C797S • EGFR mutation + MET-CEP7 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tepmetko (tepotinib) • Lazcluze (lazertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/02/2024","start_date":" 02/02/2024","primary_txt":" Primary completion: 09/30/2029","primary_completion_date":" 09/30/2029","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2023-10-30"},{"id":"14f82f5c-e429-4d17-9a3b-88bdc7d125c9","acronym":"ROME","url":"https://clinicaltrials.gov/study/NCT04591431","created_at":"2021-01-19T20:28:32.767Z","updated_at":"2025-02-25T13:53:27.554Z","phase":"Phase 2","brief_title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","source_id_and_acronym":"NCT04591431 - ROME","lead_sponsor":"Fondazione per la Medicina Personalizzata","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-03"},{"id":"952c0c39-ad39-476d-90fc-c92d7fa765f6","acronym":"INSIGHT","url":"https://clinicaltrials.gov/study/NCT01982955","created_at":"2021-01-17T17:35:00.093Z","updated_at":"2025-02-25T14:49:47.416Z","phase":"Phase 1/2","brief_title":"Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)","source_id_and_acronym":"NCT01982955 - INSIGHT","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • MET amplification • MET overexpression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • MET overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gefitinib • pemetrexed • Tepmetko (tepotinib)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 12/23/2013","start_date":" 12/23/2013","primary_txt":" Primary completion: 12/12/2017","primary_completion_date":" 12/12/2017","study_txt":" Completion: 10/14/2021","study_completion_date":" 10/14/2021","last_update_posted":"2022-11-08"},{"id":"869cd077-33a9-420c-94df-1752da142ec0","acronym":"EMR 200095_005","url":"https://clinicaltrials.gov/study/NCT02115373","created_at":"2021-01-18T09:47:20.164Z","updated_at":"2025-02-25T14:49:51.204Z","phase":"Phase 1/2","brief_title":"c-Met Second-Line Hepatocellular Carcinoma","source_id_and_acronym":"NCT02115373 - EMR 200095_005","lead_sponsor":"Merck KGaA, Darmstadt, Germany","biomarkers":" MET • AFP","pipe":"","alterations":" ","tags":["MET • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Tepmetko (tepotinib)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 05/18/2014","start_date":" 05/18/2014","primary_txt":" Primary completion: 02/14/2018","primary_completion_date":" 02/14/2018","study_txt":" Completion: 02/14/2018","study_completion_date":" 02/14/2018","last_update_posted":"2022-08-24"},{"id":"96636132-56a0-489e-b340-1ee6924108e9","acronym":"EMR200095_001","url":"https://clinicaltrials.gov/study/NCT01014936","created_at":"2021-01-18T03:58:46.209Z","updated_at":"2025-02-25T16:00:11.342Z","phase":"Phase 1","brief_title":"First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT01014936 - EMR200095_001","lead_sponsor":"EMD Serono","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tepmetko (tepotinib)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 11/30/2009","start_date":" 11/30/2009","primary_txt":" Primary completion: 10/31/2015","primary_completion_date":" 10/31/2015","study_txt":" Completion: 10/31/2015","study_completion_date":" 10/31/2015","last_update_posted":"2022-08-24"},{"id":"eed948ec-f54f-4d77-a639-6f8523d85923","acronym":"","url":"https://clinicaltrials.gov/study/NCT05439993","created_at":"2022-06-30T15:54:15.357Z","updated_at":"2024-07-02T16:36:07.802Z","phase":"Phase 1b/2","brief_title":"Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma","source_id_and_acronym":"NCT05439993","lead_sponsor":"Hallym University Medical Center","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2022-07-04"},{"id":"e988c68a-972c-40e5-a0a1-839cc67fa062","acronym":"KCSG AL19-17","url":"https://clinicaltrials.gov/study/NCT04647838","created_at":"2021-01-19T20:39:57.650Z","updated_at":"2025-02-25T16:10:50.659Z","phase":"Phase 2","brief_title":"Tepotinib in Solid Tumors Harboring MET Alterations","source_id_and_acronym":"NCT04647838 - KCSG AL19-17","lead_sponsor":"Chungbuk National University Hospital","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/16/2020","start_date":" 01/16/2020","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2020-12-02"}]